Tag
Menopausal hormone therapy remains the most effective treatment for estrogen deficiency symptoms, with a favorable benefit-risk profile when individualized by age, timing, and formulation. Emerging evidence refines safety perceptions, guidi
Initiation of menopausal hormone therapy during perimenopause or early postmenopause in women with vasomotor symptoms is associated with a reduced cardiovascular risk, especially among Black women and those starting therapy within 10 years
This article reviews evidence-based integrative medicine approaches for menopause, including lifestyle, mind-body therapies, nutrition, botanicals, and acupuncture, emphasizing nonhormonal options for symptom relief and health optimization.
A large Australian longitudinal study found that women with both hot flushes and night sweats had slightly higher odds of retirement, suggesting menopausal symptom burden may influence workforce participation.
A WHI secondary analysis finds that oral conjugated estrogens (with or without MPA) relieve vasomotor symptoms in women 50–59 without clear ASCVD harm, but starting HT in women ≥70 is associated with increased atherosclerotic cardiovascular
Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2
OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean diff
Bayer’s Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable
The AMY Study highlights vasomotor symptoms, particularly hot flushes, as key indicators of perimenopause onset, challenging traditional cycle-based definitions and underscoring the need for tailored symptom management across diverse reprod
This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.
This review synthesizes evidence on mobile digital therapeutics targeting vasomotor and behavioral health symptoms in menopausal and midlife women, highlighting efficacy, engagement, and implications for scalable symptom management.
The FDA delays its review of Bayer’s elinzanetant, a novel treatment for menopause-related vasomotor symptoms, by 90 days, citing the need for additional data assessment.
